Достоверный диагноз СКВ при наличии 4 критериев: должен присутствовать

1 клинический +1 иммунологический или морфологические признаки люпус-нефрита + антинуклеарные антитела/анти-ДНК.

Итого критериев: __ клинических,____ иммунологических.

 

'

 

Список использованной литературы.

.

'

'

1.Wallace D.J. The history of antimalarials.Lupus,1996,5 (suppl.),S2-S3.

2. Avina-Zubieta J.A.,Galindo-Rodriguez G., Newman S. et al. Long term effectiveness of

Antimalarial drugs in rheumatic diseases. Ann Rheum Dis 1998;57: 582-7.

3. Клюквина Н.Г.,Насонов Е.Л. Применение аминохинолиновых препаратов

в ревматологии,Русский мед.журнал,2009, 17(3),165-9.

4. Picot S. Chloroquine inhibits tumor necrosis factor production by human macrophages

in vitro. J.Infect.Dis. 1991, 164,830-831.

5.Sperber K.,Quaraishi H.,Kalb T.H. et al. Selective regulation of cytokine secretion by

hydroxychloroquine: inhibition of interleukine 1 alpha and interlukine 6 in human monocyte

and T cell.J.Rheum,1993,20:803-808.

6. Sacre K.,Criswell L.A.,McCune J.M. Hydroxychloroquine is assotiaded with impaired

interferon-alpha and tumor necrosis factor- alpha production by plasmacytoid cells in systemic

lupus erythematosus. Arthr Res Therapy,2012,14(3),R 155.

7. Castedoat-Chalumean N.,Dunoque B.,Morel N. et al. Hydroxychloroquine: a multifaceted

therapy in lupus. Presse Med,2014,43,167-180. doi: 10.1016 / j.lpm.2014.P03.007

8. Rainsford K.D.,Parke A.,Clifford-Rashotte M. et al. Therapy and pharmacological properties

of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus and

rheumatoid arthritis and related diseases. Inflammopharmacology, 2015,23(5),231-269.

9. Silva J.C.,Mariz H.A.,Oliveira P.S. et al. Hydroxychloroquine decreases Th-17 –related

cytokines in systemic lupus erythematosus and rheumatoid arthritis. Clinics (San Paulo),

2013,68 (6):766-71.

10.Tam L.S.,Gladman D.D.,Hallett D. et al. Effect of antimalarial agents on the fasting lipid

profile in systemic lupus erythematosus. J Rheumatol., 2000, 27(9), 2142-2145.

11.Morris S.J., Wasko M.C.,Antohe J.L.. et al. Hydroxychloroquine use associated with

improvment in lipid profiles in rheumatoid arthritis patients. Arthr Care Res (Hoboken),

2011,63(4), 530-534. doi: 10.1002/acr.20393

12.Pareek A.,Chandurkar N.,Thulaseedharan N.V.. et al. Efficacy and safety of fixed dose

combination of atorvastatin and hydroxychloroquine: a randomized, double-blind

comparison with atorvastatin alone among Indian patients with dyslipidemia. Curr Med

Res Opin. 2015,31(11),2105-17. doi: 10.1185/03007995.2015.1087989

13. Charles-Schoerman C., Wang X., Lee Y.Y. et al. Association of Triple therapy with

Improvement in cholesterol profiles over two year follow-up in the TEAR trial. Arthr

Rheum,2015, nov.25. doi: 10.1002/art.39502

14.Desai R.J., Eddings W, Liao K.P.. et al. DMARD use and risk of incindent hyperlipidemia

in patients with early rheumatoid arthritis. Arthr Care Research, 2015,67,457-466.

15. Kerr g.,Aujero M.,Richards J. et al. Associations of hydroxychloroquine use with lipid

profiles in rheumatoid arthritis: pharmacologic implications. Athr Care Res (Hoboken),

2014,66(11),1619-26. doi: 10.1002/acr.22341

16.Virdis A., Tani C., Duranti E. et al. Early treatment with hydroxychloroquine prevents the

development of endothelial dysfunction in a murine model of systemic lupus erythematosus.

Arthritis Res Ther,2015,17,277/ doi: 10.1186/s 13075-015-0790-3

17.Achunhan S.,Ahlunalia J., Shafig N.. et al. Hydroxychloroquine efficacy as an antiplatelet

agent study in healthy volunteers: a proof of concept study. Cardiovasc Pharmacol Ther, 2015,

20(2),174-80. doi:10.1177/1074248414546324

18. Sharma T.S.,Wasko M.C.,Nang X. et al. Hydroxychloroquine use is associated with

decreased incident cardiovascular events in rheumatoid arthritis patients. J Am Heart Assoc.,

2016,5(1). Pii: e 00

19.Wasko M.C.,Hubert H.B., Ligala V.B. et al.. Hydroxychloroquine and risk of diabetes in

patients with rheumatoid arthritis. JAMA,2007, 298,187-193.

20. Penn S.K., Kao A.H., Schott L.L.. et al. Hydroxychloroquine and glyctmia in women with

rheumatoid arthritis and systemic lupus erythematosus. J Rheum,2010,37(6).1136-42.

doi: 10.3899/jrheum.09094

21. Rekedal L.R.,Massarotti E.,Garg R.. et al. Changes in glycosylated hemoglobin after

initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with

rheumatic diseases. Arthr Rheum,2010,62(12),3569-73.doi: 10.1002/art.27703

22. Solomon D.H., Massarotti E., Garg R.. et al. Association between DMARD and diabetes

Risk in patients with rheumatoid arthritis and psoriasis. JAMA,2011,305(24),2525-31.

doi:10.1001/jama.2011.878

23. Solomon D.H., Garg R.. et al. Effect of hydroxychloroquine on insulin sensitivity and

lipid parametes in rheumatoid arthritis patients without diabetes mellitus: a randomized,

blinded crossover trial. Arthr Care Res (Hoboken),2014,66(8)<1246-51/

24.Chen Y.M.,Lin C.H.,Lan T.H.. et al.. Hydroxychloroquine reduces risc of incident diabetes

mellitus in lupus patients in dose-dependent manner: a population- based cohort study.

Rheumatology (Oxford), 2015,54(7),1244-9.doi:10.1093/rheumatology/keu 451

25.Насонов Е.Л.,Каратеев Д.Е.,Балабанова Р.М. Ревматоидный артрит. Ревматология.

Национальное руководство.Под редакцией Е.Л.Насонова, В.А.Насоновой.

Москва, ГЭОТАР-Медиа, 2008,290-331.

26. Ревматология. Клинические рекомендации. Под редакцией Е.Л.Насонова.

Москва, ГЭОТАР-Медиа,2010, 133-134,141-142.

27. Каратеев Д.Е.,Олюнин Ю.А.,Лучихина Е.Л.Новые классификационные

критерии ревматоидного артрита ACR/EULAR 2010- шаг вперед к ранней

диагностике.Научно-практическая ревматология,2011,1,10-15

28. Van der Heijde D.M.,van Riel P.L.,Nuver-Zwart I.H.. et al. Effect of hydroxychloroquine

and sulfasalasine on progression of joint damage in rheumatoid arthritis. Lancet, 1989,

1(8646):1036-8.

29. O' Dell J.R. Combination DMARD therapy with hydroxychloroquine, sulfasalazine, and methotrexate. Clin.Exp.Rheumatol.,1999,17,53-8/

30. O' Dell J.R., Leff R., PaulsenG. et al.Treatment of rheumatoid arthritis with methotrexate

and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of three

medications:results of a two-year randomized, double-blind, placebo-controlled trial.

Arthr.Reum.,2002,46,5,1164-1170.

31. Cummins L.,Katikireddi V.S.,Shankaranaraijana S.. et al. Safety and retention of

combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.

Intern.Med.J.,2015,45(12),1266-73.doi:10.1111/imj.12896

32.Чичасова Н.В., Имаметдинова Г.Р.,Насонов Е.Л. Место плаквенила в современной

терапии ревматодного артрита. Русский медицинский журнал,2009,17(3),487-490.

33.. Tsakonas E.,Fitzgerald A.A., Fitzgerald M.A. et al. Consequences of delayed therapy

with second-line agents in rheumatoid arthritis: a 3 year followup on the

hydroxychloroquine in early rheumatoid arthritis (HERA) study. J.Rheum.,2000,27(3),

623-628.

34. Hurst S.,Kallan M.J.,Wolf F.J. et al. Methotrexate, hydroxychloroquine and intramuscular

gold in rheumatoid arthritis: relative area under the curve effectivness and sequence effects.

J.Rheum.,2002,29,1639-1645.

35. Das S.K., Pareek A.,Mathur D.S. et al. Efficacy and safety of hydroxychloroquine sulphate

in rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial:

an Indian experience. Curr.Med.Res.Opin., 2007,23,2227-2234.

36.De Jong P.H.,Hazes J.M.,Barenndregt P.J. et al. Induction therapy with a combination of

DMARDs is better than methotrexate monotherapy: first results of the tREACH trial.

Ann Rheum Dis. 2013; 72(1):72-8

37. Moreland L.W., O' Dell J.R., Paulus H. et al. TEAR: treatment of early aggressive RA; A

Randomized,double-blind,2-year trial comparing immediate triple DMARD versus MTX

plus etanercept to step-up from initial MTX monotherapy. Arthritis Rheum.,2012;64(9)

2824-35.

38. O' Dell J.R., Mikuls T.R. Therapies for active rheumatoid arthritis after methotrexate

failure. New Engl J Med, 2013,369,307-18. doi: 10.1056/NEJMoa.1303006.

39. Karlsson J.A., Neovins M.,Nilsson J.A.. et al. Addition of infliximab compared with

addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid

arthritis: 2-year quality-of-life results of the randomized, controlled, SWEFOT trial.

Ann Rheum Dis,2013,72(12), 1927-33.

40.Saag K.G.,Teng G.G.,Patkar N.M. et al. «American College of Rheumatology 2008

Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying

Antirheumatic Drugs in Rheumatoid Arthritis». Arthr. Care and Res.,2008,59:762-784.

41. Генно-инженерные биологические препараты в лечении ревматоидного артрита.

Ред.академика РАМН Е.Л.Насонова.ИМА ПРЕСС,Москва,2013,стр.549.

42.Smolen J.,Aletaha D.,Bijsma J.W. et al. Treating rheumatoid arthritis to target:

recommendations of an international task force. AnnRheum Dis,2010,69(4),631-7. doi:

10.1136/ard.2009.12319.

43.Насонов Е.Л.,Мазуров В.И.,Каратеев Д.Е. и др. Проект рекомендаций по лечению

ревматоидного артрита Общероссийской общественной организации «Ассоциация

ревматологов России»-2014.Научно-практ.ревмат.,2014,5 (52),477-494

44. Балабанова Р.М.,Гукасян Д.А.,Шахраманова Е.Л.,Горячев Д.В.Эффективность и

безопасность гидроксихлорохина иммарда при РА по данным открытого

неконтролируемого исследования в амбулаторной практике. Научно-практ. ревмат.,

2012,6,42- 4

45.Клюквина Н.Г. Системная красная волчанка. Ревматология.

Национальное руководство.Под редакцией Е.Л.Насонова, В.А.Насоновой. Москва,

ГЭОТАР-Медиа, 2008,419-446.

46. Bertsias G., Ioannidis J.,Boletis J. et al. EULAR recommendations for the management of

systemic lupus erythematosus. Report of Task Force of the EULAR Standing Committee for

International Clinical Studies Including Therapeutics. Ann.Rheum.Dis.,2008,67:195-205.

47.Mosca M., Tani C., Aringer M. et al. European League Against Rheumatis recommendations

for monitоring patients with systemic lupus erythematosus in clinical practice and in

observational studies. Ann.Rheum.Dis., 2010; 69(7): 1269-1274.

48. Клюквина Н.Г.,Насонов Е.Л. Аминохинолиновые производные при системной

красной волчанке:новые перспективы. Русский медицинский журнал,2012; 20(7);

360-366.

49. Соловьев С.К.,Асеева Е.А. Системная красная волчанка. Современные критерии

диагноза, мониторинг активности и рекомендации по терапии. Пособие для врачей.

Под ред. Насонова Е.Л. Киев. Морион; 2013.,47 стр.

50. Соловьев С.К.,Асеева Е.А.,Попкова Т.В. и др. Стратегия лечения красной волчанки

«до достижения цели» (Treat to Target SLE)/Рекомендации международной рабочей

группы и комментарии российских экспертов.Научно-практ.ревматология,2015,(53) 1,

9-16.

51. Ruiz-Irastorza G., Ramos-Casls M.,Brito-Zeron P. et al. Clinical efficasy and side effects of

antimalarials in systemic lupus erythematosus; a systemic review. Ann.Rheum.Dis., 2010,

69,20-28.

9-16.

52..Fessler B.,Alarcon G., McGwin G et al. Systemic lupus erythematosus in three ethnic

groups,XVI.Association of hydroxychloroquine use with reduced risk of damage accrual.

Arthr.Rheum.,2005,52,1473-1480.

53.Akhavan P.S.,Su J.,Lou W. et al. The early protective effect of hydroxychloroquine on the

risk of cumulative damage in patients with systemic lupus erythematosus. J Rheum, 2013,

40(6): 831-41.

54. Alarcon G., McGwin G.,Bertoli A. et al. Effect of hydroxychloroquine on the survival of

patients with systemic lupus erythematosus, date from LUMINA, a multiethnic US cohort

(LUMINA L). Ann.Rheum.Dis.,2007,66,1168-1172

55. Ruiz-Irastorza G.,Egurbide M.,Pijoan J. et al. Effect of antimalarials on thrombosis and

survival in patients with systemic lupus erythematosus. Lupus, 2006, 15, 577-583.

56. Costedoat-Chalumeau N., Galicier L., Aumaitre O. et al. Hydroxychloroquine in systemic

lupus erythematosus, results of a French multicentre controlled trial (PLUS study). Ann.

Rheum.Dis., 2013,72(11), 1786-92.Doi: 10.1136/annrheumdis-2012-202322.

57. Carmichael S.J., Day R.O.,Tett S.E. A cross-sectional study of hydroxychloroquine

concentrations and effects in people with systemic lupus erythematosus. Intern Med J,

2013,43(5), 547-53.

58. Durcan L.,Clarke W.A.,Magder L.S. et al. Hydroxychloroquine blood levels in systemic

lupus erythematosus clarifying dosing controversies and improving adherence. J Rheum,

42(11),2092-7.

59.Costedoat-Chalumeau N.,Amoura Z. et al. Safety of hydroxychloroquine in pregnant patients

with connective tissue diseases, a study of one hundred thirty-three cases compared with a

control group. Arthritis Rheum.,2003,48,3207-3211.

60. Motta M., Tincani A. Follow-up of infants exposed to hydroxychloroquine given to mothers

during pregnancy and lactation. J.Perinatol., 2005,25,86-89.

61. Clowse M.,Magder L.,Witter F. et al. Hydroxychloroquine in lupus pregnancy.

Arthr.Rheumat.,2006, 54,3640-3647.

62. Costedoat-Chalumeau N., Dunogue B., Morel N. et al. Hydroxychloroquine: a multifaceted

treatment in lupus. Presse Med., 2014,43(6): 167-80

63. Desai R.J.,Huybrechts K.F.,Bateman B.T. et al. Patterns and secular trends in use of

immunomodulatory agents during pregnancy in women with rheumatologic conditions.

Arthr Rheum,2015, nov.25 doi:10.1002/art.33521

64 Клюквина Н.Г., Насонов Е.Л. Фармакотерапия системной красной волчанки:

современные рекомендации. РМЖ,2010,18(18),1108-13.

65. Casado E.,Gratacos J.,Tolosa C. et al. Antimalarial myopathy: an underdiagnosed

complication? Prospective longitudinal study of 119 hatients. Ann Rheumat Dis, 2006,

65:385-90.

66. Costedoat-Chalumeau N., Hulot J., Amoura Z. Et al. Heart conduction disoders related to

antimalarials toxicity, an analysis of electrocardiograms in 85 patients treated with

hydroxychloroquine for connective tissue diseases. Rheumatology (Oxford), 2007,46,808-10.

67. Wozniacka A.,Cygankiewicz I., Chudzik M. et al.The cardiac safety of chloroquine

Phosphate treatment in hatients with systemic lupus erythematosus, the influence on

arrhythmia, heart rate variability and repolarization parameters. Lupus,2006,15,521-25.

.

 

 

.